Abstract
Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Serelaxin: New Investigational Treatment in Acute Heart Failure
Volume: 11 Issue: 3
Author(s): Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Acute heart failure, cardiac failure, cardiovascular diseases, cognitive impairment, dyspnea, hospitalized patients, ischemic cardiomyopathy, non-ischemic cardiomyopathy, relaxin, serelaxin, vasodilator.
Abstract: Over the last decade several pharmacological approaches for acute heart failure have been introduced, however, no drastic change in the medical management apart from device-dependent therapy was observed. Essentially vasodilators and diuretics as primary therapy in acute heart failure was discussed and encouraged in the guidelines but no breakthrough in the treatment of acute heart failure was achieved. More recently, clinical trials of relaxin and its recombinant form, i.e., serelaxin in patients with acute heart failure demonstrated a significant clinical improvement with favorable safety and tolerability profile in symptomatic heart failure patients. This report reviews the potential beneficial effects and role of serelaxin in the setting of acute heart failure.
Export Options
About this article
Cite this article as:
Said Sarmad and Mukherjee Debabrata, Serelaxin: New Investigational Treatment in Acute Heart Failure, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/1871525711666131128144132
DOI https://dx.doi.org/10.2174/1871525711666131128144132 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions
Current Pharmaceutical Design Targeting Gender Difference in the Introduction of New Drugs for Diabetes Mellitus and Metabolic Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies New Strategies for Metabolic Support in Cancer
Current Nutrition & Food Science Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry Role of Beta2 Agonists in Respiratory Medicine with Particular Attention to Novel Patents and Effects on Endocrine System and Immune Response
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry Orthopaedic Applications of Gene Therapy
Current Gene Therapy Effect of Hypoxia on Cytochrome P450 Activity and Expression
Current Drug Metabolism Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety The Role of Radiopharmaceuticals in Amiodarone-Induced Thyroid Pathology
Current Radiopharmaceuticals Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Prevalence of Congenital Heart Disease among Children in Khorramabad (West of Iran)
Cardiovascular & Hematological Disorders-Drug Targets Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews